Neuromuscular Disease

2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
1 program
1
nexiguran ziclumeranPhase 3
Intellia Therapeutics
1 program
1
nexiguran ziclumeranPhase 31 trial
Active Trials
NCT06672237Active Not Recruiting50Est. Aug 2028

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
Intellia Therapeuticsnexiguran ziclumeran

Clinical Trials (1)

Total enrollment: 50 patients across 1 trials

A Phase 3 Study of NTLA-2001 in ATTRv-PN

Start: Nov 2024Est. completion: Aug 202850 patients
Phase 3Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space